Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANOQUAN vs CEPHULAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.
Hypertension
Treatment of constipation,Hepatic encephalopathy (portal-systemic encephalopathy) including the prevention and treatment of coma
100 mg orally twice daily
30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 7-10 hours (renal impairment: prolonged); systemic absorption is minimal (<3%) after oral administration, so half-life reflects clearance of absorbed fraction.
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Not absorbed; metabolized by colonic bacteria (e.g., Lactobacillus, Bacteroides) to low molecular weight organic acids.
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Primarily renal (20-30% as unchanged drug) and fecal (up to 70% as unmetabolized drug via biliary elimination; following gastric acid-mediated degradation, only 5-10% reaches urine as intact lactulose; hepatic metabolism is negligible).
Approximately 90% bound to albumin.
Negligible (<5%): lactulose does not bind significantly to albumin or other plasma proteins due to its hydrophilic nature.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
0.5-1.0 L/kg (estimated from systemic absorption studies; limited data due to minimal absorption; reflects distribution largely into extracellular water).
Oral: 60-70% due to first-pass metabolism.
Oral: <3% (due to poor absorption and extensive metabolism by colonic bacteria; most of the drug remains in the gut lumen). Rectal: similar to oral, as systemic absorption is minimal.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
No dose adjustment required for renal impairment as lactulose is minimally absorbed and primarily acts locally in the colon.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Not specifically adjusted based on Child-Pugh score; dose is titrated to achieve desired stool frequency; caution in severe hepatic impairment due to risk of electrolyte disturbances.
Not approved for pediatric use; no established dosing
Infants: 2.5-10 m L/day in divided doses; older children: 10-25 m L/day; adolescents: 15-30 m L/day; all for constipation; for hepatic encephalopathy, doses as low as 5-10 m L 3-4 times daily with dose adjusted to produce 2-3 soft stools per day.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
Initiate at lower end of dosing range (15-30 m L/day) due to increased risk of dehydration and electrolyte imbalance; monitor for diarrhea and adjust accordingly.
No FDA black box warning.
None
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Electrolyte imbalance with prolonged use, especially in debilitated patients,Diarrhea may cause fluid and electrolyte loss,Galactose intolerance (contraindicated in patients requiring low galactose diet due to lactose content in some preparations),Monitor serum electrolytes in patients receiving high doses for hepatic encephalopathy
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
Patients requiring a low-galactose diet (lactulose contains galactose and lactose),Intestinal obstruction,Suspected gastrointestinal obstruction or perforation
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
No specific food interactions. Avoid concurrent use with other laxatives unless directed. High-fiber foods may enhance effect; ensure adequate fluid intake.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks have been identified in any trimester.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
Lactulose is not excreted into breast milk due to minimal systemic absorption. It is considered compatible with breastfeeding. M/P ratio: Not applicable (negligible absorption).
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
No dose adjustment required. Pharmacokinetics are unchanged in pregnancy due to lack of systemic absorption. Standard dosing of 15-30 m L (10-20 g) once daily, up to 60 m L/day in divided doses, is appropriate.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Cephulac (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. In hepatic encephalopathy, titrate to produce 2-3 soft stools per day. Monitor serum electrolytes, especially in elderly or renal impairment. Onset of action for constipation may be 24-48 hours. Do not confuse with other lactose-containing products.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
Take exactly as prescribed; may take 24-48 hours to produce a bowel movement.,For hepatic encephalopathy, maintain 2-3 soft stools daily; do not skip doses.,May cause bloating, gas, or cramping initially; usually resolves.,Do not take other laxatives without consulting your doctor.,Report severe diarrhea, vomiting, or muscle cramps to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANOQUAN vs CEPHULAC, answered by our medical review team.
ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. CEPHULAC is a Laxative that works by Lactulose, a synthetic disaccharide, is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form short-chain fatty acids (e.g., lactic, acetic, formic acids), which acidify the colonic contents. In hepatic encephalopathy, the acidic environment converts ammonia (NH3) to ammonium (NH4+), which is poorly absorbed and excreted in feces. Additionally, the osmotic effect of lactulose draws water into the colon, softening stools and increasing bowel movements.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANOQUAN and CEPHULAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANOQUAN is: 100 mg orally twice daily. The standard adult dose of CEPHULAC is: 30-45 m L (6.67-10 g lactulose) orally 3-4 times daily for constipation; for hepatic encephalopathy, 30-45 m L orally 3-4 times daily titrated to produce 2-3 soft stools per day, or 300 m L in 700 m L of water or saline as retention enema for 30-60 min every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANOQUAN and CEPHULAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . CEPHULAC is classified as Category C. Lactulose (CEPHULAC) is not absorbed systemically; therefore, fetal exposure is negligible. Animal studies have not shown teratogenic effects. In clinical practice, no fetal risks . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.